Literature DB >> 6732386

High-output right ventricular failure secondary to hepatic arteriovenous microfistulae. Selective arterial embolization treatment.

D Brohée, P Franken, M Fievez, M Baudoux, C Hénuzet, P Brasseur, J Struyven.   

Abstract

A patient with diffuse hepatic arteriovenous microfistulae suffered from secondary high-output right ventricular failure, pulmonary hypertension, and ascites, all of which could be managed by selective embolization of the hepatic artery. The vascular lesion of the liver seems to be essential, although hemorrhagic hereditary telangiectasia , perhaps aggravated by administration of oral contraceptives, may be considered contributory factors in this case.

Entities:  

Mesh:

Year:  1984        PMID: 6732386     DOI: 10.1001/archinte.1984.00350180230033

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  5 in total

1.  Hibernating kidney - a case report.

Authors:  Henna Kalsi; Paul Wennberg; Sanjay Misra; Leslie Cooper
Journal:  Int J Angiol       Date:  2009

2.  High Output Cardiac Failure.

Authors:  Inder S. Anand; Viorel G. Florea
Journal:  Curr Treat Options Cardiovasc Med       Date:  2001-04

Review 3.  Interventional treatment of hepatic arterial and venous pathology: a commentary.

Authors:  J Rösch; B D Petersen; L D Hall; K Ivancev
Journal:  Cardiovasc Intervent Radiol       Date:  1990 Jun-Jul       Impact factor: 2.740

4.  Clinical outcome of transfemoral embolisation in patients with arteriovenous malformations of the liver in hereditary haemorrhagic telangiectasia (Weber-Rendu-Osler disease).

Authors:  M Caselitz; S Wagner; A Chavan; M Gebel; J S Bleck; A Wu; H J Schlitt; M Galanski; M P Manns
Journal:  Gut       Date:  1998-01       Impact factor: 23.059

5.  Hepatic artery embolization for treatment of patients with hereditary hemorrhagic telangiectasia and symptomatic hepatic vascular malformations.

Authors:  Ajay Chavan; Martin Caselitz; Karl-Friedrich Gratz; Joachim Lotz; Timm Kirchhoff; Plinio Piso; Siegfried Wagner; Michael Manns; Michael Galanski
Journal:  Eur Radiol       Date:  2004-08-17       Impact factor: 5.315

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.